IgG2 as an independent risk factor for mortality in patients with community-acquired pneumonia

Journal of Critical Care

Volumn 35, Issue , 2016, Pages 115-119

  de la Torre, Mari C ^a   Palomera, Elisabet ^a   Serra Prat, Mateu ^a   Güell, Estel ^a   Yébenes, Joan Carles ^a   Bermejo Martín, Jesús F ^b   Almirall, Jordi ^a,c,d  

^a HOSPITAL DE MATARÓ   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Community acquired pneumonia; IgG2; Immunoglobulin; Intensive care unit; Mortality; Prognosis

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; BIOLOGICAL MARKER; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFORMED CONSENT; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; RISK FACTOR; APACHE; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROPORTIONAL HAZARDS MODEL; SPAIN; SURVIVAL ANALYSIS;

AGED; APACHE; BIOMARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPAIN; SURVIVAL ANALYSIS;

EID: 84994469049     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2016.05.005     Document Type: Article

References (27)

1. [1] Woodhead, M.A., Macfarlane, J.T., McCracken, J.S., Rose, D.H., Finch, R.G., Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1 (1987), 671–674.
2. [2] Jokinen, C., Heiskanen, L., Juvonen, H., Kallinen, S., Karkola, K., Korppi, M., et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 137 (1993), 977–988.
3. [3] Almirall, J., Bolíbar, I., Vidal, J., Sauca, G., Coll, P., Niklasson, B., et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15 (2000), 757–763.
4. [4] Sligl, W.I., Marrie, T.J., Severe community-acquired Pneumonia. Crit Care Clin 29 (2013), 563–601.
5. [5] Almirall, J., Mesalles, E., Klamburg, J., Parra, O., Agudo, A., Prognostic factors of pneumonia requiring admission to the Intensive Care Unit. Chest 107 (1995), 511–516.
6. [6] Torres, A., Peetermans, W.E., Viegi, G., Blasi, F., Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68 (2013), 1057–1065.
7. [7] Venet, F., Gebeile, R., Bancel, J., Guignant, C., Poitevin-Later, F., Malcus, C., et al. Assessment of plasmatic immunoglobulin G, A and M levels in septic shock patients. Int Immunopharmacol 11 (2011), 2086–2090.
8. [8] Taccone, F.S., Stordeur, P., De Backer, D., Creteur, J., Vincent, J.L., Gamma-globulin levels in patients with communitiy-acquired septic shock. Shock 32 (2009), 379–385.
9. [9] Tamayo, E., Fernández, A., Amansa, R., Carrasco, E., Goncalves, L., Heredia, M., et al. Beneficial role of endogenous immunoglobulin subclasses and isotypes in septic shock. J Crit Care 27 (2012), 616–622.
10. [10] Bermejo-Martin, J.F., Rodriguez-Fernandez, A., Herrán-Monge, R., Andaluz-Ojeda, D., Muriel-Bombín, A., Merino, P., et al. GRECIA Group (Grupo de Estudios y Análisis en Cuidados Intensivos). Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276:4 (2014), 404–412.
11. [11] Andaluz-Ojeda, D., Iglesias, V., Bobillo, F., Almansa, R., Rico, L., Gandía, F., et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care, 15, 2011, R243.
12. [12] Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (2007), S27–S72.
13. [13] British Thoracic Society, BTS guidelines for the management of community acquired pneumonia in adults. Thorax 56:IV (2001), 1–64.
14. [14] Malbrain, M.L., De Laet, I., Should I give my septic patients polyclonal gamma-globulins if they are hypogammaglobulinemic?. Shock 33 (2010), 337–338.
15. [15] Herer, B., Labrousse, F., Mordelet-Dambrine, M., Durandy, A., Offredo-Hemmer, C., Ekindjian, O., et al. Selective IgG subclass deficiencies and antibody responses to pneumococcal capsular polysaccharide antigen in adult community-acquired pneumonia. Am Rev Respir Dis 142 (1990), 854–857.
16. [16] Feldman, C., Mahomed, A.G., Mahida, P., Morar, R., Schoeman, A., Mpe, J., et al. IgG subclasses in previously healthy adult patients with acute community-acquired pneumonia. S Afr Med J 86 (1996), 600–602.
17. [17] Gordon, C.L., Johnson, P.D., Permezel, M., Holmes, N.E., Gutteridge, G., McDonald, C.F., et al. Association between severe pandemic 2009 influenza A (H1N1) virus infection and immunoglobulin G(2) subclass deficiency. Clin Infect Dis 50 (2010), 672–678.
18. [18] Gordon, C.L., Holmes, N.E., Grayson, M.L., Torresi, J., Johnson, P.D., Cheng, A.C., et al. Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin Vaccine Immunol 19 (2012), 446–448.
19. [19] de la Torre, M.C., Bolíbar, I., Vendrell, M., de Gracia, J., Vendrell, E., Rodrigo, M.J., et al. Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respir Med 107 (2013), 2038–2045.
20. [20] Bermejo-Martín, J.F., Rodriguez-Fernandez, A., Herrán-Monge, R., Andaluz-Ojeda, D., Muriel-Bombín, A., Merino, P., et al. Immunoglobulins IgG1, IgM and IgA: a synesgistic team influencing survival in sepsis. J Intern Med 276 (2014), 404–412.
21. [21] Justel, M., Socias, L., Almansa, R., Ramírez, P., Gallegos, M.C., Fernandez, V., et al. IgM levels in plasma predict outcome in severe pandemic influenza. J Clin Virol 58 (2013), 564–567.
22. [22] Alejandria, M.M., Lansang, M.A.D., Dans, L.F., Mantaring, J.B., Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev(1), 2002, CD001090, 10.1002/14651858.CD001090.
23. [23] Kreymann, K.G., de Heer, G., Nierhaus, A., Kluge, S., Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 35 (2007), 2677–2685.
24. [24] Norrby-Teglund, A., Haque, K.N., Hammarström, L., Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med 260 (2006), 509–516.
25. [25] Cavazzuti, I., Serafini, G., Busani, S., Rinaldi, L., Biagioni, E., Buoncristiano, M., et al. Early therapy with IgM-enriched polyclonal immunoglobulin in patients with septic shock. Intensive Care Med 40 (2014), 1888–1896.
26. [26] Berlot, G., Vassallo, M.C., Busetto, N., Bianchi, M., Zornada, F., Rosato, I., et al. Relationxhip between the timing of administration of IgM and IgA enriched immunoglobulins in patients with severe sepsis and septic shock and the outcome: a retrospective analysis. J Crit Care 27 (2012), 167–171.
27. [27] Welte, T., Dellinger, R.P., Ebelt, H., Ferrer, M., Opal, S.M., Schliephake, D.E., et al. Concept for a study design in patients with severe community-acquired pneumonia: A randomized controlled trial with a novel IGM-enriched immunoglobulin preparation – the CIGMA study. Respir Med 109 (2015), 758–767.